Skip to main content
. 2021 Aug 20;12:669965. doi: 10.3389/fimmu.2021.669965

Figure 1.

Figure 1

Vaccination scheme and dendritic cell (DC) characterization. (A) Patient interventions, before NAC, patients have gone to an apheresis collection to obtain peripheral blood mononuclear cells (PBMCs) and therefore induce monocyte-derived DCs (cryopreserved until use). After four doses of chemotherapy, a new blood sample was taken to compare between pre- and post-chemotherapy. (B) Representative histograms of immature DCs (red), alpha DCs (blue), and standard DCs (yellow), comparing the expression levels of CD86, CD209, CCR7, CD80, CD83, and HLA-DR. (C) Clinical trial scheme per patient in weeks, week 0 is referred to the first dose of chemotherapy, the process starts with the evaluation criteria for patients (w-2), apheresis (vaccinated group) or blood sample (control group) was taken in w-1. Between doses of chemotherapy, we transferred two doses of DCs for a total of six doses. One week after the fourth dose of A/C, we collect the second blood sample.